Compare AFYA & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AFYA | PGEN |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2019 | 2013 |
| Metric | AFYA | PGEN |
|---|---|---|
| Price | $13.42 | $3.66 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $17.00 | $7.67 |
| AVG Volume (30 Days) | 90.3K | ★ 4.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | $14.67 | $342.78 |
| Revenue Next Year | $7.84 | $478.46 |
| P/E Ratio | $9.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.12 | $1.11 |
| 52 Week High | $19.76 | $5.47 |
| Indicator | AFYA | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 31.69 | 33.80 |
| Support Level | N/A | $3.49 |
| Resistance Level | $15.35 | $5.10 |
| Average True Range (ATR) | 0.40 | 0.36 |
| MACD | -0.12 | -0.13 |
| Stochastic Oscillator | 10.95 | 1.57 |
Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.